clinical trial · NCT06799247
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Myasthaenia GravisDecartes-08Placebo Drug
brief summary
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
started
May 6, 2025
primary completion
Nov 30, 2026
completion
Sep 30, 2027
last updated
Mar 24, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol